

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	MERGER
EFFECTIVE DATE:	04/03/2008

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Bradley Pharmaceuticals, Inc.		04/03/2008	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	Nycomed US Inc.
Street Address:	60 Baylis Road
City:	Melville
State/Country:	NEW YORK
Postal Code:	11747
Entity Type:	CORPORATION: NEW YORK

PROPERTY NUMBERS Total: 18

Property Type	Number	Word Mark
Registration Number:	2252000	ENTSOL
Registration Number:	2256099	ENTSOL
Registration Number:	3055472	ADOXA PAK
Registration Number:	3266005	KEROL
Serial Number:	77312938	ZODERM HYDRATING WASH
Registration Number:	2877819	ZODERM
Registration Number:	2800890	ROSULA
Registration Number:	0721545	LIDA-MANTLE
Registration Number:	0721546	LIDA-MANTLE-HC
Serial Number:	78938573	RELIEF PAD
Registration Number:	3276943	REDI-CLOTHS
Registration Number:	3447691	AFIRM
Registration Number:	2843401	SOLARAZE

CH \$465.00 2252000

Registration Number:	3026918	ADOXA DOXYCYCLINE TABLETS SMALL. EASY TO SWALLOW.
Registration Number:	2725852	ADOXA
Registration Number:	2399228	A-FIL
Registration Number:	2197069	AFIRM
Registration Number:	1612636	BENZASHAVE

CORRESPONDENCE DATA

Fax Number: (651)686-7111
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 651-259-2302
Email: ljoyce@ip-firm.com
Correspondent Name: Linda M. Byrne, Crawford Maunu PLLC
Address Line 1: 1150 Northland Drive, Suite 100
Address Line 4: St. Paul, MINNESOTA 55120

ATTORNEY DOCKET NUMBER:	BRAD.102TM
NAME OF SUBMITTER:	Linda M. Byrne
Signature:	/Linda M. Byrne/
Date:	07/10/2008

Total Attachments: 4
source=Plan of Merger of Bradley Pharmaceuticals into Nycomed US Inc-v4 Signed#page1.tif
source=Plan of Merger of Bradley Pharmaceuticals into Nycomed US Inc-v4 Signed#page2.tif
source=Plan of Merger of Bradley Pharmaceuticals into Nycomed US Inc-v4 Signed#page3.tif
source=Plan of Merger of Bradley Pharmaceuticals into Nycomed US Inc-v4 Signed#page4.tif

PLAN OF MERGER
OF
BRADLEY PHARMACEUTICALS, INC.
(a Delaware corporation)
INTO
NYCOMED US INC.
(a New York corporation)

This **PLAN OF MERGER** (this "Plan") is entered into as of April 3, 2008 between Nycomed US Inc., a New York corporation (the "Corporation"), and Bradley Pharmaceuticals, Inc., a Delaware corporation (the "Subsidiary").

RECITALS

WHEREAS, the Corporation is the owner of all of the issued and outstanding shares of capital stock of the Subsidiary; and

WHEREAS, the Corporation has authorized the merger of the Subsidiary into the Corporation pursuant to the provisions of the Business Corporation Law of the State of New York and the General Corporation Law of the State of Delaware.

AGREEMENT

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. At the Effective Time (as defined in Section 11 hereof), pursuant to the provisions of the Business Corporation Law of the State of New York and the General Corporation Law of the State of Delaware, the Subsidiary shall merge with and into the Corporation (the "Merger").
2. The Corporation shall be the surviving corporation of the Merger and shall continue as a corporation organized and existing pursuant to the laws of the State of New York under the name "Nycomed US Inc."
3. The Corporation was incorporated on November 16, 1998 under the name of Pharma, Inc., and its name was changed to Altana Inc. on December 30, 1998 and to Nycomed US Inc. on August 24, 2007.

4. Following the Effective Time, the corporate existence of the Corporation, with all of its purposes, powers and objects, shall continue unaffected and unimpaired by the Merger, and as the surviving corporation, it shall, from and after the Effective Time, possess all of the rights, privileges, immunities, powers and purposes of the Subsidiary, and all of the property (real, personal and intangible), causes of action and every other asset of the Subsidiary shall vest in the Corporation, and the Corporation shall assume all of the obligations and liabilities of the Subsidiary, all without further act or deed.

5. The separate corporate existence of the Subsidiary shall cease upon the effectiveness of the Merger.

6. At the Effective Time, all shares of stock of the Subsidiary which are issued and outstanding or held as treasury stock immediately prior to the Merger shall automatically, by virtue of the Merger and without any action on the part of the holder thereof, be cancelled and cease to exist without payment of any consideration with respect thereto.

7. The Certificate of Incorporation and Bylaws of the Corporation, as in effect immediately prior to the Merger, shall be those of the surviving corporation.

8. The members of the board of directors and the officers of the Corporation immediately prior to the Merger shall be the members of the board of directors and the officers, respectively, of the surviving corporation until successors are appointed in accordance with applicable law and the Certificate of Incorporation and Bylaws of the surviving corporation.

9. The Subsidiary and the Corporation will cause to be executed, acknowledged, filed and reported, the Certificate of Ownership and Merger and the Certificate of Merger, and any amendment or supplements thereof, in such form and with any such changes, additions or deletions as any officer of the Subsidiary or the Corporation shall determine to be advisable and in the best interests of the Subsidiary and the Corporation, respectively, which determination shall be conclusively evidenced by such officer's execution and delivery thereof.

10. At any time prior to the time the Certificate of Ownership and Merger filed with the Secretary of State of the State of Delaware and the Certificate of Merger filed with the Department of State of the State of New York become effective, the transactions contemplated by this Plan may be abandoned and the Certificate of Ownership and Merger and the Certificate of Merger terminated in accordance with applicable law.

11. The Merger shall be effective as of 11:59 p.m. Eastern Time on April 3, 2008 (the "Effective Time").

12. The designation and number of outstanding shares of each class of the Subsidiary, all of which are owned by the Corporation, are as follows:

<u>Designation</u>	<u>Number Outstanding</u>
Common Stock	100


13. This Plan may be executed in any number of counterparts, each such counterpart being deemed to be an original instrument, and all such counterparts shall together constitute the same agreement.

14. This Plan shall be governed by and construed in accordance with the internal laws of the State of New York.

[Signature page follows.]

IN WITNESS WHEREOF, this Plan has been duly approved, executed and delivered by the parties hereto as of the date first written above.

NYCOMED US INC.

By:  _____

Name: Arthur Dulik, Jr.

Title: Senior Vice President

BRADLEY PHARMACEUTICALS, INC.

By:  _____

Name: Arthur Dulik, Jr.

Title: Senior Vice President